Monitoring weight and blood glucose in in-patients: How helpful is a protocol?

Psychiatric Bulletin

Volumn 31, Issue 3, 2007, Pages 88-91

  Runcie, Olga ^a   Boilson, Marie ^b   Hamilton, Ross ^a  

^a ROYAL CORNHILL HOSPITAL   (United Kingdom)

^b NHS TAYSIDE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

GLUCOSE; NEUROLEPTIC AGENT; OLANZAPINE; RISPERIDONE;

ADULT; ARTICLE; BLOOD GLUCOSE MONITORING; BODY WEIGHT; CLINICAL PROTOCOL; CONSULTATION; DELUSIONAL DISORDER; DIABETES MELLITUS; DRUG SUBSTITUTION; HEALTH EDUCATION; HEALTH SURVEY; HOSPITAL ADMISSION; HUMAN; MAJOR CLINICAL STUDY; MEDICAL RECORD; MENTAL PATIENT; OBESITY; OUTPATIENT; PSYCHOSIS; SCHIZOAFFECTIVE PSYCHOSIS; SCHIZOPHRENIA;

EID: 33847693128     PISSN: 09556036     EISSN: None     Source Type: Journal    
DOI: 10.1192/pb.bp.105.005934     Document Type: Article

References (14)

1. ALLISON, D. B. & CASEY, D. E. (2001) Antipsychotic-induced weight gain: a review of the literature. Journal of Clinical Psychiatry, 62 (suppl. 7), 22-31.
2. AMERICAN DIABETES ASSOCIATION et al(2004) Consensus Development Conference on Antipsychotic Drugs and Obesity and Diabetes. Journal of Clinical Psychiatry, 65, 267-272.
3. BOILSON M. & HAMILTON, R. J. (2003) A survey of monitoring of weight and blood glucose in in-patients. Psychiatric Bulletin, 27, 424-426.
4. BUSHE, C. & LEONARD, B. (2004) Association between atypical antipsychotic agents and type 2 diabetes: review of prospective clinical data. British Journal of Psychiatry, 184 (suppl. 47), 87-93.
5. CASEY, D. E., HAUPT, D.W., NEWCOMER, J.W., et al (2004) Antipsychotic-induced weight gain and metabolic abnormalities: implication for increased mortality in patients with schizophrenia. Journal of Clinical Psychiatry, 65 (suppl. 7), 4-17.
6. COMMITTEE ON SAFETY OF MEDICINES (2002) Olanzapine (Zyprexa) and diabetes. Current Problems in Pharmacovigilance, 28, 3. http://www.mhra.gov.uk
7. HAUPT, D. &NEWCOMER, J. (2001) Hyperglycaemia and antipsychotic medications. Journal of Clinical Psychiatry, 62 (suppl. 27), 15-26.
8. LEBOVITZ, H. E. (2003) Metabolic consequences of atypical antipsychotic drugs. Psychiatric Quarterly, 74, 277-290.
9. MARDER, S. R., ESSOCK, S. M., MILLER, A. L., et al (2002) The Mount Sinai Conference on the pharmacotherapy of schizophrenia. Schizophrenia Bulletin, 28, 5-16.
10. MENZA, M., VREELAND, B., MINSKY, S. et al (2004) Managing atypical antipsychotic-associated weight gain: 12 month data on a multimodal weight control program. Journal of Clinical Psychiatry, 65, 471-477.
11. SCOTTISH INTERCOLLEGIATE GUIDELINES NETWORK (1996) Obesity in Scotland. Integrating Prevention with Weight Management. http://www.sign.ac.uk/pdf/ sign8.pdfsearch=%22obesity%20in%Scotland%22
12. TAYLOR, D., PATON, C. & KERWIN, R. (2003) The Maudsley Prescribing Guidelines (7th edn).Taylor & Francis.
13. TAYLOR, D.,YOUNG, C., ESOP, R., et al (2004) Testing for diabetes in hospitalised patients prescribed antipsychotic drugs. British Journal of Psychiatry, 185, 152-156.
14. WORLD HEALTH ORGANIZATION (1992) The ICD-10 Classification of Mental and Behavioural Disorder: Clinical Descriptions and Diagnostic Guidelines. WHO.